CN215386750U

CN215386750U - Spraying agent using device for patients suffering from COPD (chronic obstructive pulmonary disease) in tracheostomy state

Info

Publication number: CN215386750U
Application number: CN202121236079.XU
Authority: CN
Inventors: 谢榕城
Original assignee: Xiamen Hospital Zhongshan Hospital Fudan University
Current assignee: Xiamen Hospital Zhongshan Hospital Fudan University
Priority date: 2021-06-03
Filing date: 2021-06-03
Publication date: 2022-01-04
Anticipated expiration: 2031-06-03

Abstract

The utility model provides a spraying agent using device for patients suffering from COPD (chronic obstructive pulmonary disease) in an tracheostomy state, which comprises a spraying agent body for storing medicines, an air bag for releasing and storing the medicines in the spraying agent body in a mist form and a tracheostomy cannula for allowing the mist stored in the air bag to enter the lung from the tracheostomy opening, wherein one end of the air bag is connected with the spraying agent body, the other end of the air bag is connected with an outer opening of the tracheostomy cannula, and an inner opening of the tracheostomy cannula is implanted into the tracheostomy of the patients. The utility model can connect the tracheotomy, so that a COPD patient inhales the vaporific medicine into the lung from the tracheotomy by the device under the tracheotomy state, thereby improving symptoms, accelerating the remission of the disease, improving the lung function, effectively reducing the hospitalization time and reducing the treatment cost.

Description

Spraying agent using device for patients suffering from COPD (chronic obstructive pulmonary disease) in tracheostomy state

Technical Field

The utility model relates to the field of medical appliances, in particular to a spraying agent using device for patients suffering from COPD in an autogenous cutting state.

Background

Chronic Obstructive Pulmonary Disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction that can further progress to the common chronic diseases of pulmonary heart disease and respiratory failure. At present, when a patient is in a trachea cannula state or an tracheotomy state, hormone and bronchodilator can improve symptoms, accelerate the remission of diseases and improve lung function for a COPD patient; however, after the patient is subjected to invasive ventilation, the patient is required to be in an off-line state, the aerosol cannot be directly inhaled through the mouth and can only be inhaled from the tracheotomy, but no device of the type is available for the patient, so that the patient can only receive treatment in a hospital, the hospitalization time is prolonged, the cost is high, and the burden of the patient is high.

SUMMERY OF THE UTILITY MODEL

Aiming at the problems that no related device in the prior art assists a COPD patient to inhale the spray from an tracheostomy, so that the hospitalization time of the user is increased and the quality cost is increased, the utility model provides a spray application device for the COPD patient in the tracheostomy state.

In order to realize the purpose of the utility model, the technical scheme adopted by the utility model is as follows:

the utility model provides a nebula use device under COPD patient's autogenous cutting state, is used for with the medicine in the nebula body is the gasbag that the mist is released and is stored and is used for supplying the autogenous cutting sleeve pipe of the interior mist of gasbag entering lung from the autogenous cutting mouth, gasbag one end is connected the nebula body, the gasbag other end is connected the outer mouthful of autogenous cutting sleeve pipe, patient's gas incision is implanted to autogenous cutting sleeve pipe's internal orifice.

Preferably, gasbag one end is equipped with and is used for the installation the first interface of nebula body, the gasbag other end is equipped with and is used for connecting the second interface of autogenous cutting sleeve pipe outer lane, be equipped with in the first interface and be used for preventing palirrhea first valve body, be equipped with in the second interface and be used for preventing palirrhea second valve body.

Preferably, the first valve body and the second valve body are both one-way valves.

Preferably, the first interface is provided with a first clamping groove, the spraying agent body is provided with a first buckle matched with the first clamping groove in a clamping manner, the second interface is provided with a second clamping groove, and the outer opening of the autogenous cutting sleeve is provided with a second buckle matched with the second clamping groove in a clamping manner.

Preferably, a sealing ring is arranged between the spraying agent body and the first interface and between the outer opening of the autogenous cutting sleeve and the second interface.

Preferably, the autogenous cutting sleeve pipe is equipped with the stationary vane, the stationary vane both sides are equipped with the fixed orifices, wear to be equipped with in the fixed orifices and be used for with the fixed band of patient's neck.

Preferably, the fixed wing is arranged on the side wall close to one end of the outer opening of the autogenous cutting sleeve, and the fixed wing and the side wall of the autogenous cutting sleeve are integrally formed.

Preferably, the fixing band is a bandage, and the bandage is provided with a mesh-shaped button for fixing and adjusting tightness.

Preferably, one end of the tracheostomy tube close to the internal opening is provided with an isolation air sac for preventing the secretion of the lung from flowing out of the incision.

The utility model has the following beneficial effects:

the utility model can connect the tracheotomy, so that a COPD patient inhales the vaporific medicine into the lung from the tracheotomy by the device under the tracheotomy state, thereby improving symptoms, accelerating the remission of the disease, improving the lung function, effectively reducing the hospitalization time and reducing the treatment cost.

Drawings

FIG. 1: the utility model has a structure schematic diagram;

in the figure: 10. a spray body; 20. an air bag; 21. a first interface; 22. a second interface; 30. Autogenous cutting sleeve pipe; 31. a fixed wing; 32. an isolation airbag.

Detailed Description

The prior art has no related device for assisting COPD patients to inhale the spraying agent from the tracheotomy, so that the user has the problems of increasing the hospitalization time and increasing the quality cost. Therefore, the present invention provides a new solution, which will be described in detail below with reference to the accompanying drawings for better clarity.

Referring to fig. 1, a spray using device in an tracheostomy state of a COPD patient comprises a spray body 10 for storing medicine, an air bag 20 for releasing and storing the medicine in the spray body 10 in a mist form, and a tracheostomy cannula 30 for allowing the mist stored in the air bag 20 to enter a lung from the tracheostomy opening, wherein one end of the air bag 20 is connected with the spray body 10, the other end of the air bag 20 is connected with an outer opening of the tracheostomy cannula 30, and an inner opening of the tracheostomy cannula 30 is implanted into the tracheostomy of the patient.

During the use, through the extrusion gasbag 20, the raw materials medicine in the spraying agent body 10 is the fog under the pressure effect and is released and save in the gasbag 20, extrudes again the gasbag 20, and the raw materials medicine in the spraying agent body 10 is the fog again under the pressure effect and is released and save in the gasbag 20, and the fog in the original gasbag 20 can be extruded to get into patient's lung through the autogenous cutting sleeve pipe 30, thereby reach and improve the symptom, accelerate the state of an illness and alleviate, improve the effect of pulmonary function.

In other embodiments, the air bag 20 may also be a compression mechanism with a cavity inside or may be a pump to atomize the drug.

In this embodiment, a first connector 21 for installing the aerosol body 10 is arranged at one end of the air bag 20, a second connector 22 for connecting an outer opening of the tracheostomy cannula 30 is arranged at the other end of the air bag 20, a first valve body for preventing backflow is arranged in the first connector 21, and a second valve body for preventing backflow is arranged in the second connector 22.

The first valve body and the second valve body are both one-way valves.

First interface 21 is equipped with first draw-in groove, nebula body 10 be equipped with first draw-in groove joint complex first buckle, second interface 22 is equipped with the second draw-in groove, autogenous cutting sleeve 30's outer mouthful department be equipped with second draw-in groove joint complex second buckle.

Sealing rings are arranged between the spraying agent body 10 and the first connector 21 and between the outer opening of the autogenous cutting sleeve 30 and the second connector 22.

The tracheostomy tube 30 is provided with a fixed wing 31, two sides of the fixed wing 31 are provided with fixed holes, and a fixed belt for fixing the neck of the patient penetrates through the fixed holes.

The fixed wing 31 is arranged on the side wall close to one end of the outer opening of the autogenous cutting sleeve 30, and the fixed wing 31 and the side wall of the autogenous cutting sleeve 30 are integrally formed.

The fixing band is a bandage, and the bandage is provided with a mesh-shaped buckle for fixing and adjusting tightness.

The tracheostomy cannula 30 is provided with an isolation balloon 32 near the end of the internal opening to prevent the flow of pulmonary secretions out of the stoma. The isolation air bag 32 is connected with an external inflation port through an air pipe, and the isolation air bag 32 is inflated or deflated through the inflation port.

Although the present invention has been described in detail in the foregoing embodiments, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the spirit and scope of the utility model.

Claims

1. A spray application device for patients with COPD under the condition of tracheostomy is characterized in that: including the nebula body that is used for saving the medicine, be used for with this internal medicine of nebula is the gasbag that the mist is liberated and is saved and is used for supplying the gastome sleeve pipe that the mist that stores in the gasbag enters into the lung from the gastome, gasbag one end is connected the nebula body, the gasbag other end is connected the outer mouthful of gastome sleeve pipe, patient's gas incision is implanted to gastome sheathed tube internal orifice.

2. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 1, characterized in that: gasbag one end is equipped with and is used for the installation the first interface of nebula body, the gasbag other end is equipped with and is used for connecting the second interface of autogenous cutting sleeve pipe outer lane, be equipped with in the first interface and be used for preventing palirrhea first valve body, be equipped with in the second interface and be used for preventing palirrhea second valve body.

3. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 2, characterized in that: the first valve body and the second valve body are both one-way valves.

4. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 2, characterized in that: the first interface is provided with a first clamping groove, the spraying agent body is provided with a first buckle matched with the first clamping groove in a clamped mode, the second interface is provided with a second clamping groove, and the outer opening of the autogenous cutting sleeve is provided with a second buckle matched with the second clamping groove in a clamped mode.

5. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 2, characterized in that: and sealing rings are arranged between the spraying agent body and the first interface and between the outer opening of the autogenous cutting sleeve and the second interface.

6. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 1, characterized in that: the autogenous cutting sleeve pipe is equipped with the stationary vane, the stationary vane both sides are equipped with the fixed orifices, wear to be equipped with in the fixed orifices and be used for with the fixed band of patient's neck.

7. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 6, characterized in that: the fixed wing sets up and is being close to the lateral wall of autogenous cutting sleeve pipe outer shed one end, the fixed wing with autogenous cutting sleeve pipe lateral wall integrated into one piece.

8. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 6, characterized in that: the fixing band is a bandage, and the bandage is provided with a mesh-shaped buckle for fixing and adjusting tightness.

9. The aerosol using device for patients with COPD under the condition of tracheostomy according to claim 1, characterized in that: one end of the tracheostomy cannula close to the inner opening is provided with an isolation air bag for preventing the secretion of the lung from flowing out of the incision.